NCL targeting increases the sensitivity of breast cancer cells to Fulvestrant treatment. (A) MTS assay performed in MCF-7 cells treated with increasing concentration of Fulvestrant (50–150 nM), transfected or treated as listed. *, P < 0.01 relative to control-treated cells. (B) Growth curves obtained by MTS assay on MCF-7F cells, cultured in standard conditions (100 nM Fulvestrant) and treated or transfected as indicated. *, P < 0.01 relative to control-transfected or untreated cells. (C) Apoptosis associated with different concentrations (100 nM [top] and 150 nM [bottom]) of Fulvestrant in MCF-7F cells treated with DCT + si-Scr, DCT + si-NCL, AS1411+ si-Scr, and AS1411 + miRNAs was evaluated at 72 h by Annexin V staining. PI, propidium iodide. (A–C) All data are presented as mean ± SD of three independent experiments performed in triplicate.